14 Einträge gefunden

1. Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study

   1. Mrowietz, Ulrich
   2. Burden, A David
   3. Pinter, Andreas
   4. Reich, Kristian
   5. Schäkel, Knut
   6. Baum, Patrick
   7. Datsenko, Yakov

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
2. Quality of psoriasis care in Germany - results from the nationwide health care studies PsoHealth 2004-2017

   1. Langenbruch, Anna
   2. Mohr, Nicole
   3. Kirsten, Nathalie
   4. Reich, Kristian
   5. von Kiedrowski, Ralph
   6. Strömer, Klaus
   7. Mrowietz, Ulrich

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial

   1. Gordon, Kenneth B
   2. Foley, Peter
   3. Krueger, James G
   4. Pinter, Andreas
   5. Reich, Kristian
   6. Vender, Ronald
   7. Vanvoorden, Veerle

   2021 - Forschungsinformationssystem des UKE
4. Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis

   1. Fahrbach, Kyle
   2. Sarri, Grammati
   3. Phillippo, David M
   4. Neupane, Binod
   5. Martel, Samantha E
   6. Kiri, Sandeep
   7. Reich, Kristian

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
5. IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study

   1. Papp, Kim A
   2. Weinberg, Mark A
   3. Morris, Alun
   4. Reich, Kristian

   2021 - Forschungsinformationssystem des UKE
6. Deutsche S3-Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm - Teil 2: Therapiemonitoring, besondere klinische Situationen und Komorbidität

   1. Nast, Alexander
   2. Altenburg, Andreas
   3. Augustin, Matthias
   4. Boehncke, Wolf-Henning
   5. Härle, Peter
   6. Klaus, Joachim
   7. Koza, Joachim

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
7. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE)

   1. Eyerich, Kilian
   2. Weisenseel, Peter
   3. Pinter, Andreas
   4. Schäkel, Knut
   5. Asadullah, Khusru
   6. Wegner, Sven
   7. Muñoz-Elias, Ernesto J

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
8. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

   1. Reich, Kristian
   2. Teixeira, Henrique D
   3. de Bruin-Weller, Marjolein
   4. Bieber, Thomas
   5. Soong, Weily
   6. Kabashima, Kenji
   7. Werfel, Thomas

   2021 - Forschungsinformationssystem des UKE
9. Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab

   1. Mehta, Heena
   2. Mashiko, Shunya
   3. Angsana, Julianty
   4. Rubio, Manuel
   5. Hsieh, Ya-Ching M
   6. Maari, Catherine
   7. Reich, Kristian

   2021 - Forschungsinformationssystem des UKE
10. Mouse models of atopic dermatitis: a critical reappraisal

    1. Gilhar, Amos
    2. Reich, Kristian
    3. Keren, Aviad
    4. Kabashima, Kenji
    5. Steinhoff, Martin
    6. Paus, Ralf

    2021 - Forschungsinformationssystem des UKE
11. Bimekizumab versus Secukinumab in Plaque Psoriasis

    1. Reich, Kristian
    2. Warren, Richard B
    3. Lebwohl, Mark
    4. Gooderham, Melinda
    5. Strober, Bruce
    6. Langley, Richard G
    7. Paul, Carle

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
12. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial

    1. Reich, Kristian
    2. Papp, Kim A
    3. Blauvelt, Andrew
    4. Langley, Richard G
    5. Armstrong, April
    6. Warren, Richard B
    7. Gordon, Kenneth B

    2021 - Forschungsinformationssystem des UKE
13. Which PASI Outcome Is Most Relevant to the Patients in Real-World Care?

    1. Kirsten, Natalia
    2. Rustenbach, Stephan
    3. von Kiedrowski, Ralph
    4. Sorbe, Christina
    5. Reich, Kristian
    6. Augustin, Matthias

    2021 - Forschungsinformationssystem des UKE - frei zugänglich
14. Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials

    1. Silverberg, Jonathan I
    2. Simpson, Eric L
    3. Wollenberg, Andreas
    4. Bissonnette, Robert
    5. Kabashima, Kenji
    6. DeLozier, Amy M
    7. Sun, Luna

    2021 - Forschungsinformationssystem des UKE - frei zugänglich